Sinapsos Podcast | Oncology

Sinapsos Podcast
  • 0.0 (0)
  • Courses
  • Updated Daily

Zero Fluff. Pure Insight. Get the latest scientific research without the small talk. We dive deep into new publications to give you clear, information-packed summaries—no filler, no chatter. Stay tuned. Stay informed.

  1. Sep 21

    E53 - Nodal Staging in Locally Advanced Lung Cancer

    E53   |  11 min   |   Latest   |  Publication Link Podcast based on: Haimi, I.; Rajaram, R. Nodal Staging in Patients with Locally Advanced Non-Small Cell Lung Cancer: Indications, Approaches, and Impact on Downstream Treatment Selection. Cancers 2026, 18, 2561. https://doi.org/10.3390/cancers18162561 Type: Review  |  Publication date: 10 August 2026 Summary: Precise mediastinal lymph node staging is fundamental to the management of locally advanced non-small cell lung cancer (NSCLC). Nodal disease status is the primary determinant of prognosis in this population and directly governs eligibility for surgery, multimodality therapy, immunotherapy, and molecularly targeted treatments. As systemic options expand and therapeutic sequencing becomes increasingly complex, accurate nodal assessment is more critical than ever. This review examines contemporary mediastinal staging approaches and illustrates how nodal evaluation drives modern treatment selection in stage II-III NSCLC. Keywords: non-small cell lung cancer; mediastinal lymph node staging; endobronchial ultrasound-guided transbronchial needle aspiration; FDG-PET/CT; neoadjuvant chemoimmunotherapy; N2 disease classification; TNM ninth edition; perioperative immunotherapy; surgical resection; multidisciplinary treatment planning   License and disclaimer: Original article © 2026 by the authors. Licensed under the Creative Commons Attribution 4.0 (CC BY 4.0) license (https://creativecommons.org/licenses/by/4.0/). This episode is an AI-generated audio adaptation of the article: the script and the voices are synthetic, changes were made, and the adaptation is not endorsed by the authors, the journal, or the publisher. It may contain errors or omissions, so consult the original publication before relying on any detail. It is for educational purposes only and is not medical advice. The creators accept no liability for any use of this content.

  2. Sep 16

    E45 - Antibody-Drug Conjugates in Contemporary Oncology

    E45   |  19 min   |   Latest   |  Publication Link Podcast based on: Philipovskiy, A.; Shurmur, S.; Abid, M.B. Antibody–Drug Conjugates in Contemporary Oncology: A Clinical Perspective on Dose Optimization, Sequencing, and Combination Strategies. Cancers 2026, 18, 2652. https://doi.org/10.3390/cancers18162652 Type: Review  |  Publication date: 17 August 2026 Summary: Antibody–drug conjugates are cancer treatments designed to deliver potent cytotoxic drugs more selectively to tumor cells by linking a tumor-directed antibody to a therapeutic payload. This review examines the structural and biologic features that determine clinical activity, including target selection, linker stability, payload class, drug-to-antibody ratio, tumor penetration, biomarkers, toxicity, and resistance. Particular attention is given to the practical questions emerging as multiple ADCs enter the same malignancies and earlier treatment settings: how to select a biologically efficient dose, how to sequence agents with overlapping targets or payloads, and how to distinguish rational combinations from combinations that merely add toxicity. The next phase of ADC development will require not only improved molecular engineering, but also a more disciplined clinical framework for selecting, dosing, sequencing, and combining these agents. Keywords: antibody–drug conjugates; dose optimization; sequencing; combination strategies; biomarkers; resistance; interstitial lung disease; linker; payload; translational oncology   Disclaimer: This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

  3. Mar 15

    E44 - Exercise Program for Cancer Fatigue

    E44   |  18 min   |   Latest   |  Publication Link Podcast based on: Cano-Uceda, A.; Pareja-García, P.; Sánchez-Rodríguez, E.; Fraguas-Ramos, D.; Martín-Álvarez, L.; Asencio-Vicente, R.; Rivero-de la Villa, A.; Pérez-Pérez, M.d.M.; Obispo-Portero, B.M.; Morales-Ruiz, L.; de Dios-Álvarez, R.; Sanchez-Barroso, L.; De Sousa-De Sousa, L.; Maté-Muñoz, J.L.; García-Fernández, P. Effects of a 6-Week Supervised Multimodal Exercise Program on Cancer-Related Fatigue, Quality of Life and Physical Function During Active Treatment: A Randomized Controlled Trial. Cancers 2026, 18, 947. https://doi.org/10.3390/cancers18060947 Type: Article  |  Publication date: 13 March 2026 Summary: Reduced quality of life, cancer-related fatigue, and functional impairment are common problems during and after cancer treatment. To examine this issue, a randomized clinical trial was conducted with 110 patients with stage I–III cancer. Participants were randomly assigned either to an intervention group, which completed a six-week supervised exercise program, or to a control group that received usual care. The exercise program included cardiorespiratory training, strength exercises, and stretching, with intensity monitored through perceived exertion. Quality of life, fatigue, functional capacity, and muscle strength were assessed. The group that completed the exercise program showed significant and clinically meaningful improvements in fatigue, global quality of life, functional capacity, and muscle strength compared with the control group. Furthermore, a higher percentage of participants in the intervention group achieved improvements considered clinically important. Among symptoms, only insomnia showed a significant reduction. Conclusion: A brief, supervised therapeutic exercise program of moderate to vigorous intensity is safe and effective for improving fatigue, quality of life, and physical function in patients with cancer, and may be suitable for integration into routine oncologic care. Keywords: therapeutic exercise; cancer; quality of life; physical function; fatigue; short-duration intervention   Disclaimer: This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

  4. Mar 15

    E43 - Endometrial Cancer Prognosis Study

    E43   |  15 min   |   Latest   |  Publication Link Podcast based on: Paratore, S.; Russo, A.; Lanzafame, K.; Blanco, G.; Giurato, E.; Bartoloni, G.; D’Asta, M.; Sapienza, M.; Bonanno, G.M.; Vallone, A.; Ettore, G.; Bordonaro, R. Prognostic Stratification of Multiple-Classifier Endometrial Cancers: Cohort Study and Meta-Analysis. Cancers 2026, 18, 929. https://doi.org/10.3390/cancers18060929 Type: Article  |  Publication date: 12 March 2026 Summary: The classification of endometrial cancer has evolved using molecular features, allowing for improved risk assessment and more personalized treatment strategies. However, a small proportion of tumors show more than one relevant molecular alteration, making their classification and clinical management more challenging. This study aimed to characterize molecular and clinicopathological profiles of multiple-classifier endometrial cancers, enhancing our understanding of their biological heterogeneity. In our patient cohort, POLEmut tumors with concurrent MMRd/MSI generally retained the POLE-associated ultramutated profile, while tumors with both MMRd/MSI and p53abn/TP53mut alterations were more often associated with more adverse clinicopathological characteristics compared to MMRd/MSI-only tumors. By integrating our data in a systematic literature review with meta-analysis, we observed that variability in reported incidence is largely driven by differences in testing strategies. These results highlight the limitations of current classification systems and emphasize the importance of more standardized molecular approaches to improve risk stratification and management in endometrial cancer. Keywords: endometrial cancer; molecular profile; clinicopathological features; multiple-classifier; POLE mutated; mismatch repair-deficient; TP53mutated; next generation sequencing   Disclaimer: This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

  5. Mar 15

    E42 - Brain Tumor Review Molecular Diversity

    E42   |  20 min   |   Latest   |  Publication Link Podcast based on: Lee, C.; Park, K.; Park, S.; Kim, M.; Hwang, J. Diffuse Leptomeningeal Glioneuronal Tumor: A Systematic Review Highlighting Molecular Heterogeneity and Survival Outcome. Cancers 2026, 18, 912. https://doi.org/10.3390/cancers18060912 Type: Systematic Review  |  Publication date: 11 March 2026 Summary: Diffuse leptomeningeal glioneuronal tumor is a very rare brain tumor that mainly affects children and young adults and often spreads along the brain and spinal cord. Because it is uncommon and difficult to diagnose, treatment strategies vary widely and clinical outcomes remain unpredictable. To address this, we reviewed all published cases reported since this tumor was first defined to summarize clinical features, genetic findings, treatments, and survival outcomes. We found that hydrocephalus and spinal involvement were common, and that surgery was associated with longer survival in selected patients. Genetic alterations affecting tumor growth–related pathways were also frequently observed. This summary of current evidence may help clinicians recognize this tumor earlier and consider appropriate management strategies. Keywords: diffuse leptomeningeal glioneuronal tumor; leptomeningeal dissemination; BRAF fusion; MAPK pathway; pediatric low-grade glioma; molecular heterogeneity; survival analysis   Disclaimer: This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

  6. Mar 15

    E41 - Lipid Changes in Leukemia Diagnosis

    E41   |  22 min   |   Latest   |  Publication Link Podcast based on: Wojnicka, J.; Kiełbus, M.; Mertowska, P.; Mertowski, S.; Grywalska, E.; Sosnowski, P.; Wielgosz, A.; Kozub-Pędrak, A.; Sosnowska-Pasiarska, B.; Klatka, M.; Klatka, J.; Błażewicz, A. Specific Lipidomic Shifts in Chronic Lymphocytic Leukemia at Diagnosis. Cancers 2026, 18, 896. https://doi.org/10.3390/cancers18060896 Type: Article  |  Publication date: 10 March 2026 Summary: Chronic lymphocytic leukemia (CLL) is a common type of adult blood cancer in which cells survive longer than normal, partly due to changes in how they process fats and other molecules for energy. This study examined the blood plasma of newly diagnosed patients who had not yet received treatment to identify unique patterns in lipid molecules. We found that patients with CLL had higher levels of certain fats, including carnitines and specific phospholipids, compared with healthy individuals. By analyzing these lipid changes using predictive bioinformatics tools, we identified that several pathways involved in lipid metabolism are likely disrupted. These findings improve our understanding of how this disease alters the body’s metabolism and could inform future research on biomarkers for earlier disease detection and treatment development. Keywords: chronic lymphocytic leukemia (CLL); metabolic reprogramming; carnitines; ether-linked phospholipids; lipidomics   Disclaimer: This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

  7. Mar 15

    E40 - Frailty Assessments in Lung Cancer Clinics

    E40   |  18 min   |   Latest   |  Publication Link Podcast based on: Pearce, J.; Hamzeh, H.; Denholm, M.; Greystoke, A.; Gomes, F.; Clegg, A.; Velikova, G.; Richards, S.H.; Gilbert, A. Clinicians’ Experiences of Implementing Clinical Frailty Scale Assessments in Lung Oncology Clinics: A Qualitative Interview Study. Cancers 2026, 18, 884. https://doi.org/10.3390/cancers18050884 Type: Article  |  Publication date: 09 March 2026 Summary: Simple frailty assessments, such as the clinical frailty scale (CFS), could support treatment decision-making and care in cancer clinics, but they are not currently used routinely. This qualitative interview study explored clinicians’ experiences of using frailty assessments in lung cancer clinics to understand how they impact care, and the barriers and facilitators to their use. Four main themes were identified. ‘Assessing fitness and frailty’ explores the central role of performance status in assessing fitness and accessing cancer treatments, as well as its limitations and what frailty assessments add. ‘Scoring and interpreting CFS’ describes the ease and relative yield of CFS use, and its ability to differentiate between patients considered ‘borderline’ according to performance status, as well as the need to consider scoring in the wider clinical context. ‘Role of frailty and impacts of assessment’ highlights how frailty assessments can enhance patient-centred care and support, communication with patients, and clinical and shared decision-making, with the potential to streamline care and convey wider system-level benefits. ‘Barriers and facilitators to implementation’ describes factors that help or hinder the delivery of frailty assessments and frailty-informed care, with specific recommendations provided to support use in practice. Keywords: frailty; geriatric oncology; qualitative research; frailty assessment; frailty screening; clinical frailty scale (CFS); frailty-informed care   Disclaimer: This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

  8. Mar 15

    E39 - Nutrition in Pediatric Cancer Care

    E39   |  19 min   |   Latest   |  Publication Link Podcast based on: Suwannaying, K.; Rujkijyanont, P.; Inaba, H. Nutritional Assessment of Children and Adolescents with Cancer in Various Resource Settings. Cancers 2026, 18, 873. https://doi.org/10.3390/cancers18050873 Type: Review  |  Publication date: 08 March 2026 Summary: Nutrition has bidirectional effects in children with cancer. It influences, and is influenced by, the disease and treatment, starting from the diagnosis and continuing through therapy into survivorship. Therefore, a longitudinal comprehensive nutritional assessment is essential to define the patient’s nutritional status and to guide management. Assessment strategies should be tailored not only to specific cancer types but also to the available health care resources. In this review, we discuss practical methods for evaluating malnutrition, including their advantages and limitations. We also provide a structured approach for use in various resource settings. This approach will guide nutritional management that can enhance treatment outcomes for children with cancer. Keywords: nutrition; assessment; children; cancer; resource-setting   Disclaimer: This podcast provides a synthetically generated voice summary and discussion of scientific publications. The views expressed do not represent the views of the original authors, journals, or publishers. This podcast uses AI-assisted summaries, so it may or may not introduce inaccuracies or omit important details. Listeners are strongly encouraged to consult the original publications or sources for full context and accuracy. This podcast is for educational and informational purposes only and does not constitute clinical advice, medical guidance, or recommendations. The creators of this podcast are not liable for any errors, omissions, or outcomes resulting from the use of the information provided.

See All (46)

About

Zero Fluff. Pure Insight. Get the latest scientific research without the small talk. We dive deep into new publications to give you clear, information-packed summaries—no filler, no chatter. Stay tuned. Stay informed.

Information

  • Creator
    Sinapsos Podcast
  • Years Active
    2025 - 2026
  • Episodes
    46
  • Rating
    Clean
  • Copyright
    © Copyright 2025 All rights reserved.
  • Show Website
    Sinapsos Podcast | Oncology